SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-22-001572
Filing Date
2022-05-16
Accepted
2022-05-16 07:30:30
Documents
48
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q bcli-20220331x10q.htm   iXBRL 10-Q 877572
2 EX-31.1 bcli-20220331xex31d1.htm EX-31.1 9384
3 EX-31.2 bcli-20220331xex31d2.htm EX-31.2 10209
4 EX-32.1 bcli-20220331xex32d1.htm EX-32.1 4853
5 EX-32.2 bcli-20220331xex32d2.htm EX-32.2 5763
  Complete submission text file 0001410578-22-001572.txt   3084974

Data Files

Seq Description Document Type Size
6 EX-101.SCH bcli-20220331.xsd EX-101.SCH 25802
7 EX-101.CAL bcli-20220331_cal.xml EX-101.CAL 27964
8 EX-101.DEF bcli-20220331_def.xml EX-101.DEF 71738
9 EX-101.LAB bcli-20220331_lab.xml EX-101.LAB 187447
10 EX-101.PRE bcli-20220331_pre.xml EX-101.PRE 152176
42 EXTRACTED XBRL INSTANCE DOCUMENT bcli-20220331x10q_htm.xml XML 357531
Mailing Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019
Business Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019 201-488-0460
BRAINSTORM CELL THERAPEUTICS INC. (Filer) CIK: 0001137883 (see all company filings)

IRS No.: 207273918 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36641 | Film No.: 22925459
SIC: 2836 Biological Products, (No Diagnostic Substances)